Saxenda obesity drug market performance?

Short answer: Saxenda has underperformed relative to Wegovy in recent years. Wegovy’s rapid uptake and higher efficacy have dominated Novo Nordisk’s obesity portfolio, and Saxenda’s sales growth has slowed or declined in many markets.

Key points
- What Saxenda is: Liraglutide 3 mg, daily injection for obesity/weight management (BMI 30+ or 27+ with comorbidities).
- Competitive landscape: Wegovy (semaglutide 2.4 mg weekly) has been the big driver of Novo Nordisk’s obesity growth since its launch, due to superior weight loss results and the convenience of weekly dosing. Other competitors (Contrave, Qsymia) remain in the market but have not matched Wegovy’s momentum.
- Market dynamics: Since Wegovy’s launch (and especially through 2022–2024), Saxenda has seen reduced share of Novo Nordisk’s obesity sales and slower growth, with many patients and payers favoring Wegovy for obesity treatment when appropriate.
- Regional variation: The US market has been the key battleground; Europe and other regions have shown slower uptake for Saxenda as Wegovy expands.
- Label and pricing factors: Saxenda remains a niche option for patients who may not be eligible for Wegovy or who tolerate/adhere to daily dosing. Payer coverage and high list prices continue to influence access and utilization.
- Outlook: Near-term trajectory skews toward continued dominance of Wegovy in obesity care. Saxenda could stabilize at a smaller, niche role or gradually decline, unless there are changes in labeling, new indications, or shifts in payer dynamics that expand its use.

Would you like me to pull the latest publicly reported sales figures for Saxenda and Wegovy (by year or by quarter) and provide a sourced summary? I can also tailor the data to a specific region (U.S., EU, etc.) if you’d prefer.